Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-06-29, Stock:ABBV, The news for the past five days is as follows:
2020-06-22: NEWS1: The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern.NEWS2: Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?.NEWS3: The Extreme Risks of Trading Your Own Retirement Assets - June 22, 2020.NEWS4: FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity.
2020-06-23: NEWS1: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.NEWS2: AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA.NEWS3: IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM).
2020-06-24: NEWS1: Here are the factors, and the stocks, that will help you play the COVID-19 market.NEWS2: Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict.NEWS3: 3 Stocks to Buy on New Drug Approvals by FDA.
2020-06-25: NEWS1: The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY.NEWS2: Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine.NEWS3: Sosei, AbbVie sign drug discovery deal worth up to $1 billion.
2020-06-26: NEWS1: Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio.NEWS2: The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts.NEWS3: AbbVie's Eye Disorder Candidate Gets Complete Response Letter.NEWS4: How gene therapy and CRISPR are helping to cure blindness.NEWS5: Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol.

Answer: Rise